Publications by authors named "Roy L Hawke"

Claim this Profile
C
Common Herbal Dietary Supplement-Drug Interactions.
Gary N Asher, Amanda H Corbett, Roy L Hawke

Am Fam Physician· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers.
Gary N Asher, Ying Xie, Ruin Moaddel, Mitesh Sanghvi, Katina S S Dossou, Roy L Hawke

J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.
Ying Xie, Sonia R Miranda, Janelle M Hoskins, Roy L Hawke

Molecules· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.
Julie C Lauffenburger, Christina L Mayer, Roy L Hawke, Kim L R Brouwer, Michael W Fried

Eur J Gastroenterol Hepatol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.
Kathleen Köck, Ying Xie, Roy L Hawke, Nicholas H Oberlies, Kim L R Brouwer

Drug Metab Dispos· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Katarina Ilic, Roy L Hawke, Ranjit K Thirumaran, Erin G Schuetz, J Heyward Hull

Drug Metab Dispos· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract.
Dina Halegoua-De Marzio, Walter K Kraft, Constantine Daskalakis, Xie Ying, Roy L Hawke

Clin Ther· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Michael W Fried, Victor J Navarro, Nezam Afdhal, Steven H Belle, Abdus S Wahed, Roy L Hawke

JAMA· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.
K Rajender Reddy, Steven H Belle, Michael W Fried, Nezam Afdhal, Victor J Navarro, Roy L Hawke

Clin Trials· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Sarah J Schrieber, Roy L Hawke, Zhiming Wen, Philip C Smith, K Rajender Reddy

Drug Metab Dispos· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
Roy L Hawke, Sarah J Schrieber, Tedi A Soule, Zhiming Wen, Philip C Smith

J Clin Pharmacol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).
Sonia R Miranda, Jin Kyung Lee, Kim L R Brouwer, Zhiming Wen, Philip C Smith, Roy L Hawke

Drug Metab Dispos· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.
Sarah J Schrieber, Zhiming Wen, Manoli Vourvahis, Philip C Smith, Michael W Fried, Roy L Hawke

Drug Metab Dispos· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.
Patrick J Roberts, Kristan D Rollins, Angela D M Kashuba, Mary F Paine, Andrew C Nelsen, Roy L Hawke

Drug Metab Dispos· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.
Zhiming Wen, Todd E Dumas, Sarah J Schrieber, Roy L Hawke, Michael W Fried

Drug Metab Dispos· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Nina Isoherranen, Shana R Ludington, Raymond C Givens, Jatinder K Lamba, Susan N Pusek, Roy L Hawke

Drug Metab Dispos· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Warfarin dosing and the promise of pharmacogenomics.
Todd E Dumas, Roy L Hawke, Craig R Lee

Curr Clin Pharmacol· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimycotic drug discovery in the age of genomics.
John D Cleary, Larry A Walker, Roy L Hawke

Am J Pharmacogenomics· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity.
Craig R Lee, Roy L Hawke, John A Pieper

Eur J Clin Pharmacol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes.
Jeffrey A Sunman, Roy L Hawke, Edward L LeCluyse, Angela D M Kashuba

Drug Metab Dispos· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Stacy S Shord, Stephanie R Faucette, Heidi H Gillenwater, Scott L Pescatore, Roy L Hawke

Cancer Chemother Pharmacol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes.
Celeste Lindley, Geraldine Hamilton, Jeannine S McCune, Stephanie Faucette, Stacy S Shord, Roy L Hawke

Drug Metab Dispos· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis